Congruent with these psychopharmacological conclusions and the types of experience-dependent plasticity that have been observed in this system (see Sections 1A and 2A), KOR antagonists have shown preclinical potential in the treatment of depression- and addiction-like behaviors. The gene discussed is OPRK1; the disease is depressive symptom measurement.